Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

PURPOSE: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking. A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that mavorixafor favorably modulates immune cell profi...

Description complète

Détails bibliographiques
Auteurs principaux: Andtbacka, Robert H.I., Wang, Yan, Pierce, Robert H., Campbell, Jean S., Yushak, Melinda, Milhem, Mohammed, Ross, Merrick, Niland, Katie, Arbeit, Robert D., Parasuraman, Sudha, Bickley, Kris, Yeung, Cecilia CS, Aicher, Lauri D., Smythe, Kimberly S., Gan, Lu
Format: Online Article Texte
Langue:English
Publié: American Association for Cancer Research 2022
Sujets:
Research Article
Accès en ligne:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010370/
https://www.ncbi.nlm.nih.gov/pubmed/36923305
http://dx.doi.org/10.1158/2767-9764.CRC-22-0090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010370/
https://www.ncbi.nlm.nih.gov/pubmed/36923305
http://dx.doi.org/10.1158/2767-9764.CRC-22-0090

Documents similaires